我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

他汀类药物的多效性及其在心血管疾病中的应用

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2011年第6期
页码:
804-806，810
栏目:
综述
出版日期:
2011-12-25

文章信息/Info

Title:
-
作者:
毕学苑; 贺 熙; 臧伟进
西安交通大学医学院药理学系，陕西 西安 710061
Author(s):
-
关键词:
他汀类药物; 多效性; 心血管疾病
Keywords:
-
分类号:
R972.6
DOI:
-
文献标识码:
A
摘要:
他汀类药物（statins）通过抑制内源性胆固醇合成限速酶还原酶，使细胞内胆固醇合成减少，是治疗动脉粥样硬化（AS）的基本药物。研究表明，他汀类药物还存在着非胆固醇依赖的多效性，包括改善血管内皮功能，抑制血管平滑肌增殖，促进血管新生，抗炎、抗氧化以及减轻血管和心肌重构等。这种“多效性”在急性心肌梗死、心肌肥大以及心力衰竭等心血管疾病的防治中发挥着重要作用。
Abstract:
-

参考文献/References

[1]叶明翔,裴建明.他汀类药物的功与过:降血脂药的使用新理念[J].心脏杂志,2010,22(3): 433-436.

[2]Zhou Q,Liao JK.Pleiotropic effects of statins.-Basic research and clinical perspectives-[J].Circ J,2010,74(5):818-826.

[3]Virdis A,Colucci R,Versari D,et al.Atorvastatin prevents endothelial dysfunction in mesenteric arteries from spontaneously hypertensive rats: role of cyclooxygenase 2-derived contracting prostanoids[J].Hypertension,2009,53(6):1008-1016.

[4] Chang CZ,Wu SC,Lin CL,et al.Atorvastatin preconditioning attenuates the production of endothelin-1 and prevents experimental vasospasm in rats[J].Acta Neurochir (Wien),2010,152(8):1399-1406.

[5]Erbs S,Beck EB,Linke A,et al.High-dose rosuvastatin in chronic heart failure promotes vasculogenesis,corrects cardiac remodeling - Results from a randomized, double-blind, and placebo-controlled study[J].Int.J Cardiol,2011,146(1):56-63.

[6]Matsumura M,Fukuda N,Kobayashi N, et al.Effects of atorvastatin on angiogenesis in hindlimb ischemia and endothelial progenitor cell formation in rats[J].J Atheroscler Thromb,2009,16(4):319-326.

[7]Li M,Liu Y,Dutt P,et al. Inhibition of serotonin-induced mitogenesis, migration, and ERK MAPK nuclear translocation in vascular smooth muscle cells by atorvastatin[J].Am J Physiol Lung Cell Mol Physiol,2007,293(2):463-471.

[8]Steffens S,Montecucco F,Mach F.The inflammatory response as a target to reduce myocardial ischaemia and reperfusion injury[J].Thromb Haemost,2009,102(2):240-247.

[9]Gomez-Garre D,Gonzalez-Rubio ML,Munoz-Pacheco P,et al.Rosuvastatin added to standard heart failure therapy improves cardiac remodelling in heart failure rats with preserved ejection fraction[J].Eur J Heart Fail,2010,12(9):903-912.

[10]Thuc LC,Teshima Y, Takahashi N,et al.Mitochondrial K(ATP) channels-derived reactive oxygen species activate pro-survival pathway in pravastatin-induced cardioprotection[J].Apoptosis,2010,15(6): 669-678.

[11]Makabe S,Takahashi Y,Watanabe H,et al.Fluvastatin protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway[J].Atherosclerosis,2010,213(2):377-384.

[12]Bot L,Jukema JW,Lankhuizen IM,et al.Atorvastatin inhibits plaque development and adventitial neovascularization in ApoE deficient mice independent of plasma cholesterol levels［J］. Atherosclerosis,2011,214(2):295-300.

[13]Ryoo S,Bhunia A,Chang F,et al.OxLDL-dependent activation of arginase II is dependent on the LOX-1 receptor and downstream RhoA signaling[J].Atherosclerosis,2011,214(2):279-287.

[14]Sun YM,Tian Y,Li X,et al.Effect of atorvastatin on expression of IL-10 and TNF-alpha mRNA in myocardial ischemia-reperfusion injury in rats[J].Biochem Biophys Res Commun,2009,382(2):336-340.

[15]Teshima Y,Yufu K,Akioka H,et al. Early atorvastatin therapy improves cardiac function in patients with acute myocardial infarction[J].J Cardiol,2009,53(1):58-64.

[16]Vilahur G,Casani L,Pena E,et al.Induction of RISK by HMG-CoA reductase inhibition affords cardioprotection after myocardial infarction[J].Atherosclerosis,2009,206(1):95-101.

[17]Qin YW,Ye P,He JQ,et al.Simvastatin inhibited cardiac hypertrophy and fibrosis in apolipoprotein E-deficient mice fed a“Western-style diet”by increasing PPAR alpha and gamma expression and reducing TC, MMP-9, and Cat S levels[J].Acta Pharmacol Sin, 2010, 31(10):1350-1358.

[18]Choi EY, Chang W, Lim S, et al. Rosuvastatin inhibits norepinephrine-induced cardiac hypertrophy via suppression of Gh[J].Eur J Pharmacol,2010,627(1-3):56-62.

[19]Desai MY,Watanabe MA,Laddu AA,et al.Pharmacologic modulation of parasympathetic activity in heart failure[J].Heart Fail Rev,2011,16(2):179-193.

备注/Memo

备注/Memo:
收稿日期：2011-04-07.基金项目：国家自然科学基金重点项目资助（30930105，30873058）； 国家重点基础研究发展973计划项目资助（2007CB512005）； 中华医学基金会杰出教授奖资助（F510000/G16916404） 通讯作者：臧伟进，教授，主要从事心血管生理药理学研究Email：zwj@mail.xjtu.edu.cn 作者简介：毕学苑，硕士生Email：vickeymu.1103@stu.xjtu.edu.cn
更新日期/Last Update: 2011-12-27